China Weight Loss Drug Industry Development Analysis and Investment Prospect Research Report (2023-2030) Obesity and overweight pose a serious threat to human health, according to WHO statistics, 202

Research Report on the Development Analysis and Investment Prospect of China's Weight Loss Drug Industry (2023-2030)

According to the WHO, more than 2.6 billion people worldwide were affected by overweight/obesity in 2020, and more than 4 billion people are expected to be affected by 2035, and the obesity rate will rise from 14% in 2020 to 24%. China's obesity rate is also growing rapidly, with 18% of Chinese adults meeting the obesity standard in 2022 with a BMI ≥ 30kg/m². China follows a tertiary prevention strategy for obesity treatment, and drug treatment is one of the important means, but its use in China is relatively conservative, and the choice of weight-loss drugs is limited. China's weight loss drug market is also constantly changing, and in 2023, Novo Nordisk's marketing application for semaglutide injection, a therapeutic biologic, was officially accepted.